WASHINGTON, D.C. ( September 26 ) -- Yesterday, President Trump announced  sweeping tariffs of 100% on brand-name and patented...

September 13th -- or 9/13 Day -- is a reminder of the harmful provision in the Inflation Reduction Act commonly known as the pill...

Incubate executive director John Stanford was recently featured in an Inside Health Policy  article by reporter Gabrielle Wanneh on the pressures facing the pharmaceutical industry under President Trump's Most Favored Nation (MFN) drug pricing proposal, among other policy headwinds.  While companies are publicly emphasizing growth, Stanford cautioned that beneath the surface the investment ecosystem is being reshaped by policies like the Inflation Reduction Act's pill penalty

WASHINGTON, D.C. ( July 31 ) -- Today, the Trump administration announced  a 60-day deadline for 17 leading pharmaceutical manufacturers...

Incubate executive director John Stanford was recently featured in a WSJ Pro: Venture Capital  article by reporter Brian Gormley on the ORPHAN Cures Act, a provision of the recently passed One Big Beautiful Bill Act. The new law addresses a critical flaw in the Inflation Reduction Act that has unintentionally disincentivized investment in rare disease research. Stanford highlighted the role of small biotech firms in driving innovation for rare diseases and emphasized the broa